XARELTO
Total Payments
$143.2M
Transactions
1,578,948
Doctors
183,812
Companies
8
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $6.3M | 77,001 | 35,335 |
| 2023 | $7.5M | 118,387 | 44,557 |
| 2022 | $20.1M | 202,985 | 62,286 |
| 2021 | $16.5M | 268,320 | 66,637 |
| 2020 | $9.5M | 129,538 | 39,520 |
| 2019 | $24.4M | 251,219 | 58,837 |
| 2018 | $24.2M | 248,306 | 58,012 |
| 2017 | $34.6M | 283,192 | 61,439 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $67.8M | 28,259 | 47.3% |
| Food and Beverage | $31.0M | 1,510,599 | 21.6% |
| Unspecified | $30.4M | 3,758 | 21.2% |
| Consulting Fee | $5.3M | 2,074 | 3.7% |
| Travel and Lodging | $5.2M | 16,062 | 3.7% |
| Grant | $1.9M | 4 | 1.3% |
| Space rental or facility fees (teaching hospital only) | $1.5M | 1,073 | 1.0% |
| Education | $153,595 | 17,118 | 0.1% |
| Gift | $48.84 | 1 | 0.0% |
Payments by Type
General
$112.8M
1,575,190 transactions
Research
$30.4M
3,758 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DCRI Learning Registry | Janssen Scientific Affairs, LLC | $7.1M | 0 |
| A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events Hospitalization and Death in Medically Ill Outpatients With Acute Symptomatic Coronavirus Disease 2019 COVID19 Infection | Janssen Research & Development, LLC | $3.3M | 0 |
| Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism | Janssen Research & Development, LLC | $2.3M | 0 |
| A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER) | Janssen Research & Development, LLC | $1.4M | 0 |
| Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II) (ORBIT-AF II) | Janssen Research & Development, LLC | $1.2M | 0 |
| Scrips Health DBA Scripps Genomic Medicine mHealth Screening To Prevent Strokes | Janssen Scientific Affairs, LLC | $1.0M | 0 |
| An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention | Janssen Scientific Affairs, LLC | $905,525 | 0 |
| (DCRI) Rivaroxaban in Prevention of Thrombotic Events in Patients with Recent Acute Coronary Syndrome study | Janssen Research & Development, LLC | $883,425 | 0 |
| Outpatient Treatment of Pulmonary Embolism and Deep Vein Thrombosis with Rivaroxaban / Impact on Emergency Department Efficiency and Patient Safety | Janssen Research & Development, LLC | $668,927 | 0 |
| ARAMIS (Addressing Real-world Anticoagulant Management Issues in Stroke) Registry at DCRI | Janssen Scientific Affairs, LLC | $609,020 | 0 |
| A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure | Janssen Research & Development, LLC | $581,466 | 0 |
| Rivaroxaban (Xarelto) for Cancer-Associated Venous Thromboembolic Disease | Janssen Research & Development, LLC | $532,867 | 0 |
| A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Diseas | Janssen Research & Development, LLC | $504,889 | 0 |
| PCSCVMA0011 | Janssen Scientific Affairs, LLC | $419,171 | 0 |
| Safety of Oral Anticoagulants Registry: A National, Hospital-Based, Sentinel Surveillance Study of the Clinical and Economic Impact of Bleeding and Bleeding Concerns due to the Use of Oral Anticoagulants | Janssen Research & Development, LLC | $379,253 | 0 |
| A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome GEMINI ACS 1 | Janssen Research & Development, LLC | $367,985 | 0 |
| Research Agreement between Janssen Scientific Affairs, LLC and Duke University Stroke Prevention in Atrial Fibrillation | Janssen Scientific Affairs, LLC | $352,680 | 0 |
| Understanding PAD Management Patterns In An Integrated Healthcare System To Identify Opportunities To Improve Clinical Outcomes In Overall ASCVD Risk Reduction and Management With a Focus on PAD | Janssen Scientific Affairs, LLC | $351,980 | 0 |
| Beth Israel Deaconess Med Center ATLAS ACS 2 TIMI 51 | Janssen Research & Development, LLC | $327,000 | 0 |
| MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department (MERCURY PE) | Janssen Research & Development, LLC | $318,413 | 0 |
Top Doctors Receiving Payments for XARELTO — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Charlotte, NC | $388,784 | 387 |
| , MD | Emergency Medicine | Effingham, IL | $385,203 | 393 |
| , MD | Emergency Medicine | Southfield, MI | $363,885 | 475 |
| , MD | Emergency Medicine | Mount Vernon, OH | $363,008 | 441 |
| William French | — | Torrance, CA | $358,601 | 289 |
| , MD | Cardiovascular Disease | Elmhurst, IL | $357,687 | 857 |
| , D.O | Adult Congenital Heart Disease | New York, NY | $354,512 | 389 |
| , M.D | Cardiovascular Disease | Elgin, IL | $349,998 | 435 |
| , MD | Cardiovascular Disease | Houma, LA | $341,174 | 233 |
| , MD | Internal Medicine | Los Angeles, CA | $329,717 | 330 |
| , M.D | Cardiovascular Disease | La Mesa, CA | $329,172 | 417 |
| , D.O | Geriatric Medicine | Copley, OH | $323,569 | 433 |
| , MD | Cardiovascular Disease | Florissant, MO | $321,791 | 437 |
| , M.D | Cardiovascular Disease | Eatontown, NJ | $320,863 | 271 |
| , MD | Internal Medicine | New Hyde Park, NY | $320,205 | 331 |
| , M.D | Interventional Cardiology | Davenport, IA | $317,968 | 217 |
| , MD | Emergency Medicine | Tampa, FL | $315,620 | 333 |
| Tamam Mohamad | Cardiovascular Disease | Dearborn, MI | $312,644 | 275 |
| , M.D | Medical Oncology | San Antonio, TX | $305,681 | 293 |
| , D. O | Internal Medicine | Temple, TX | $303,917 | 593 |
| , M.D | Cardiovascular Disease | Chicopee, MA | $303,034 | 448 |
| , M.D | Internal Medicine | Lincoln, NE | $299,112 | 254 |
| , M.D., PHD | Adult Congenital Heart Disease | New York, NY | $298,031 | 363 |
| , MD | Cardiovascular Disease | Peoria, AZ | $293,397 | 298 |
| , M.D | Cardiovascular Disease | San Juan, PR | $279,849 | 280 |
Ad
Manufacturing Companies
- Janssen Pharmaceuticals, Inc $109.9M
- Janssen Research & Development, LLC $18.5M
- Janssen Scientific Affairs, LLC $14.8M
- Johnson & Johnson Health Care Systems Inc. $16,418
- Janssen Biotech, Inc. $9,470
- Actelion Pharmaceuticals US, Inc. $564.42
- Biosense Webster, Inc. $412.62
- Johnson & Johnson Vision Care, Inc. $21.44
Product Information
- Type Drug
- Total Payments $143.2M
- Total Doctors 183,812
- Transactions 1,578,948
About XARELTO
XARELTO is a drug associated with $143.2M in payments to 183,812 healthcare providers, recorded across 1,578,948 transactions in the CMS Open Payments database. The primary manufacturer is Janssen Pharmaceuticals, Inc.
Payment data is available from 2017 to 2024. In 2024, $6.3M was paid across 77,001 transactions to 35,335 doctors.
The most common payment nature for XARELTO is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($67.8M, 47.3% of total).
XARELTO is associated with 20 research studies, including "DCRI Learning Registry" ($7.1M).